Engineered Biotherapeutic Agent for Treatment of Post-Traumatic Osteoarthritis
用于治疗创伤后骨关节炎的工程生物治疗剂
基本信息
- 批准号:10821518
- 负责人:
- 金额:$ 13.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-25 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAcuteAddressAdverse effectsAdverse eventAffectAmericanAnimal ModelAnimalsAnterior Cruciate LigamentAnti-Inflammatory AgentsArthralgiaArthritisBehaviorBiocompatible MaterialsBiodistributionBiological ProductsBiological Response Modifier TherapyCarrier ProteinsCartilageCartilage DiseasesCircular DichroismDegenerative DisorderDegenerative polyarthritisDevelopmentDisease ProgressionDoseEngineeringExhibitsGaitGelGoalsGrowth FactorHydrogelsHydrogenIn SituInflammatoryInjectableInjuryIntra-Articular InjectionsInvestigationJoint InstabilityJointsLife ExpectancyMarketingMechanicsMicellesModelingMolecular StructureOperative Surgical ProceduresOryctolagus cuniculusOutcomePainPatientsPharmaceutical PreparationsPhasePhysiciansPhysiologicalPreparationPreventionPreventive carePreventive treatmentPropertyProtein EngineeringProteinsPublic HealthRattusReconstructive Surgical ProceduresReplacement ArthroplastyReproducibilityRheologySalineScanning Electron MicroscopySecond Look SurgerySmall Business Technology Transfer ResearchStructureSystemTNF geneTemperatureTherapeuticTherapeutic EffectTimeToxic effectToxicologyTraumaTraumatic ArthropathyTraumatic injuryTreatment CostWeightanterior cruciate ligament rupturearthropathiesarticular cartilagebiopharmaceutical industrycartilage degradationcartilage repairchondroprotectioncommercial applicationcytokinedensitydisabilityexperienceexperimental groupfirst-in-humangood laboratory practicehuman diseasejoint inflammationjoint injurylight scatteringminimally invasivenovelpoint of carepoint of injurypre-clinicalpreclinical studypreservationpreventproduct developmentviscoelasticity
项目摘要
PROJECT SUMMARY/ABSTRACT
Post-traumatic osteoarthritis (PTOA) is a degenerative disease of cartilage brought on by traumatic injury to
the articular joints. Acute joint injury is followed by severe joint pain and inflammation. This results in much
more rapid degeneration of cartilage than in other forms of osteoarthritis, due to the joint instability caused by
trauma as well as the increase in proinflammatory cytokines that accelerate degeneration. PTOA affects 5.6
million Americans, with an estimated $11.79 billion associated with direct treatment costs for its treatment.
There are no approved treatments that stop or alter the progression of the disease, and complete degeneration
of the articular cartilage can necessitate joint replacement surgery. This may require surgical revision in
approximately 10 years, a particularly undesirable outcome in younger patients with longer life expectancies.
ProViZiGen has developed a novel protein-engineered injectable therapeutic hydrogel system, HydroGEN that
forms a gel when injected into the joint space and provides sustained delivery of an anti-inflammatory and
chondroprotective therapeutic molecule. Our recent preclinical investigation in a rabbit anterior cruciate
ligament (ACL) transection model has shown that immediate delivery of HydroGEN significantly prevents the
development of PTOA after joint injury and delivery 8 weeks after the point of injury has therapeutic effects
promoting endogenous cartilage repair. In this Phase I STTR, we aim to determine stability and lack of toxicity
of HydroGEN to establish functional gelation and establish safe dosing. In Aim I, we will determine the stability
and mechanics of HydroGEN by assessing the protein’s microstructure and macrostructure, as well as its
rheologic properties as a function of temperature and time to determine its functionality as an in situ gelling
injectable therapeutic. In Aim II, we will establish the lack of toxicity and selective biodistribution of HydroGEN
in a rat model of intraarticular injection. Successful completion of these aims will prepare ProViZiGen for filing a
BLA with the FDA, with large animal PTOA model investigation (Phase II) leading to first in human trials.
项目摘要/摘要
创伤后骨关节炎(PTOA)是一种由创伤引起的软骨退行性疾病。
关节关节。急性关节损伤之后是严重的关节疼痛和炎症。这导致了很多
软骨的退化比其他形式的骨关节炎更快,原因是关节不稳定
创伤以及加速退变的促炎细胞因子的增加。PTOA影响5.6
100万美国人,估计有117.9亿美元与其治疗的直接治疗费用有关。
目前还没有得到批准的治疗方法来阻止或改变疾病的进展,并完全退化。
关节软骨的损伤可能需要进行关节置换手术。这可能需要手术治疗
大约10年,对于预期寿命更长的年轻患者来说,这是一个特别不好的结果。
ProViZiGen开发了一种新的蛋白质工程可注射治疗水凝胶系统,氢
当注射到关节间隙时形成凝胶,并提供持续的抗炎和
软骨保护性治疗分子。我们最近对兔前十字交叉韧带的临床前研究
韧带(ACL)横断模型表明,立即输送氢气显著阻止了
关节损伤后发生PTOA并在损伤点8周后分娩具有治疗作用
促进内源性软骨修复。在这一阶段,我们的目标是确定稳定性和无毒性
用于建立功能性凝胶和安全剂量的氢气。在目标一中,我们将确定稳定性
通过评估蛋白质的微观结构和宏观结构以及它的
作为温度和时间的函数的流变性,以确定其作为原位凝胶的功能
注射疗法。在目标2中,我们将确定氢的无毒性和选择性生物分布。
在大鼠关节腔内注射的模型中。成功完成这些目标将为ProViZiGen提交
BLA与FDA合作,进行了大型动物PTOA模型研究(第二阶段),导致了人类试验的第一次。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jui Shivaji Chaugule其他文献
Jui Shivaji Chaugule的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 13.73万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 13.73万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 13.73万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 13.73万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 13.73万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 13.73万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 13.73万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 13.73万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 13.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 13.73万 - 项目类别:
Operating Grants














{{item.name}}会员




